Cargando…
Novel method to select meaningful outcomes for evaluation in clinical trials
BACKGROUND: A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and t...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499339/ https://www.ncbi.nlm.nih.gov/pubmed/34620699 http://dx.doi.org/10.1136/bmjresp-2021-000877 |
_version_ | 1784580304583786496 |
---|---|
author | McLeod, Charlie Norman, Richard Wood, Jamie Mulrennan, Siobhain Morey, Sue Schultz, André Messer, Mitch Spaapen, Kate Stoneham, Matthew Wu, Yue Smyth, Alan Blyth, Christopher Webb, Steve Mascaro, Steven Woodberry, Owen Snelling, Tom |
author_facet | McLeod, Charlie Norman, Richard Wood, Jamie Mulrennan, Siobhain Morey, Sue Schultz, André Messer, Mitch Spaapen, Kate Stoneham, Matthew Wu, Yue Smyth, Alan Blyth, Christopher Webb, Steve Mascaro, Steven Woodberry, Owen Snelling, Tom |
author_sort | McLeod, Charlie |
collection | PubMed |
description | BACKGROUND: A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and the health intervention being studied. Causal network diagrams may help researchers identify outcomes that are both clinically meaningful and likely to be causally dependent on the intervention, and endpoints that are, in turn, causally dependent on those outcomes. We aimed to (1) develop a generalisable method for selecting outcomes and endpoints in trials and (2) apply this method to select outcomes for evaluation in a trial investigating treatment strategies for pulmonary exacerbations of cystic fibrosis (CF). METHODS: We conducted a series of online surveys and workshops among people affected by CF. We used a modified Delphi approach to develop a consensus list of important outcomes. A workshop involving domain experts elicited how these outcomes were causally related to the underlying pathophysiological processes. Meaningful outcomes were prioritised based on the extent to which each outcome captured separate rather than common aspects of the underlying pathophysiological process. RESULTS: The 10 prioritised outcomes were: breathing difficulty/pain, sputum production/clearance, fatigue, appetite, pain (not related to breathing), motivation/demoralisation, fevers/night sweats, treatment burden, inability to meet personal goals and avoidance of gastrointestinal symptoms. CONCLUSIONS: This proposed method for selecting meaningful outcomes for evaluation in clinical trials may improve the value of research as a basis for clinical decisions. |
format | Online Article Text |
id | pubmed-8499339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84993392021-10-22 Novel method to select meaningful outcomes for evaluation in clinical trials McLeod, Charlie Norman, Richard Wood, Jamie Mulrennan, Siobhain Morey, Sue Schultz, André Messer, Mitch Spaapen, Kate Stoneham, Matthew Wu, Yue Smyth, Alan Blyth, Christopher Webb, Steve Mascaro, Steven Woodberry, Owen Snelling, Tom BMJ Open Respir Res Cystic Fibrosis BACKGROUND: A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and the health intervention being studied. Causal network diagrams may help researchers identify outcomes that are both clinically meaningful and likely to be causally dependent on the intervention, and endpoints that are, in turn, causally dependent on those outcomes. We aimed to (1) develop a generalisable method for selecting outcomes and endpoints in trials and (2) apply this method to select outcomes for evaluation in a trial investigating treatment strategies for pulmonary exacerbations of cystic fibrosis (CF). METHODS: We conducted a series of online surveys and workshops among people affected by CF. We used a modified Delphi approach to develop a consensus list of important outcomes. A workshop involving domain experts elicited how these outcomes were causally related to the underlying pathophysiological processes. Meaningful outcomes were prioritised based on the extent to which each outcome captured separate rather than common aspects of the underlying pathophysiological process. RESULTS: The 10 prioritised outcomes were: breathing difficulty/pain, sputum production/clearance, fatigue, appetite, pain (not related to breathing), motivation/demoralisation, fevers/night sweats, treatment burden, inability to meet personal goals and avoidance of gastrointestinal symptoms. CONCLUSIONS: This proposed method for selecting meaningful outcomes for evaluation in clinical trials may improve the value of research as a basis for clinical decisions. BMJ Publishing Group 2021-10-07 /pmc/articles/PMC8499339/ /pubmed/34620699 http://dx.doi.org/10.1136/bmjresp-2021-000877 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Cystic Fibrosis McLeod, Charlie Norman, Richard Wood, Jamie Mulrennan, Siobhain Morey, Sue Schultz, André Messer, Mitch Spaapen, Kate Stoneham, Matthew Wu, Yue Smyth, Alan Blyth, Christopher Webb, Steve Mascaro, Steven Woodberry, Owen Snelling, Tom Novel method to select meaningful outcomes for evaluation in clinical trials |
title | Novel method to select meaningful outcomes for evaluation in clinical trials |
title_full | Novel method to select meaningful outcomes for evaluation in clinical trials |
title_fullStr | Novel method to select meaningful outcomes for evaluation in clinical trials |
title_full_unstemmed | Novel method to select meaningful outcomes for evaluation in clinical trials |
title_short | Novel method to select meaningful outcomes for evaluation in clinical trials |
title_sort | novel method to select meaningful outcomes for evaluation in clinical trials |
topic | Cystic Fibrosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499339/ https://www.ncbi.nlm.nih.gov/pubmed/34620699 http://dx.doi.org/10.1136/bmjresp-2021-000877 |
work_keys_str_mv | AT mcleodcharlie novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT normanrichard novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT woodjamie novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT mulrennansiobhain novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT moreysue novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT schultzandre novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT messermitch novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT spaapenkate novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT stonehammatthew novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT wuyue novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT smythalan novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT blythchristopher novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT webbsteve novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT mascarosteven novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT woodberryowen novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials AT snellingtom novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials |